{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:16Z","timestamp":1792787296255,"version":"4.5.0"},"reference-count":53,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Roche S.p.A","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,4,18]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The addition of a programmed death-ligand 1 (PD-L1) inhibitor, either atezolizumab or durvalumab, to platinum-etoposide prolonged survival in a limited subset of patients with extensive-stage small-cell lung cancer (ES-SCLC). Preclinical studies demonstrated synergistic antitumor activity of combined vascular endothelial growth factor receptor and PD-L1 inhibition in SCLC. Since bevacizumab added to platinum-etoposide was safe and active in ES-SCLC, we investigated the efficacy of atezolizumab, bevacizumab, carboplatin, and etoposide as first-line treatment of ES-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The CeLEBrATE study is an Italian multicentric single-arm phase II trial of carboplatin (area under the curve 5 ml\/min), etoposide (100\u2009mg\/sqm), bevacizumab (7.5\u2009mg\/kg), and atezolizumab (1,200\u2009mg) every 3 weeks (q3w) for four to six courses, followed by bevacizumab and atezolizumab maintenance q3w in patients with ES-SCLC and no contraindications to immunotherapy or antiangiogenic therapy. Patients with asymptomatic brain metastases were eligible. Prophylactic cranial irradiation and consolidation thoracic external radiotherapy were not permitted while on study treatment. Primary endpoint was overall survival (OS) rate at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>53 patients were enrolled (45.3%\u2009women, median age 65 years) and received at least one dose of study treatment. At a median follow-up time of 23.4 months (95% CI: 21.1 to 26.0), the 1-year OS rate was 61.8% (90% CI: 50.7% to 72.8%; p=0.04), with a median OS of 12.9 months (95% CI: 11.6 to 17.5). Median progression-free survival was 6.2 months (95% CI: 5.4 to 6.6) and objective response rate was 83.3% (95% CI: 69.8% to 92.5%). Grade 3\u20134 adverse events were reported in 34 patients (64.2%) leading to dose reductions in 24 (45.3%), and dose delays in 39 (73.9%) and 32 (69.6%) during the induction and maintenance phase, respectively. 19 (35.8%) treatment-related serious adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CeLEBrATE study met its primary objective demonstrating a signal of efficacy of bevacizumab, atezolizumab, carboplatin, and etoposide in the first-line treatment of patients with ES-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>GOIRC-01\u20132019\u2009ML41241, Eudract Number: 2019-003798-2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010694","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T02:10:13Z","timestamp":1746670213000},"page":"e010694","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-7630","authenticated-orcid":false,"given":"Giuseppe","family":"Lamberti","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy"},{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Rihawi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mazzoni","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Medical Oncology Unit, Department of Oncology, Careggi University Hospital, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Riccardi","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Medical Oncology Unit, Azienda Ospedaliera Cardarelli, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Follador","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Frassoldati","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Department of Oncology, Azienda Ospedaliero Universitaria di Ferrara-Arcispedale Sant'Anna, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Colantonio","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Medical Oncology Unit, S. Croce e Carle General Hospital, Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bonetti","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Department of Oncology, \"Mater Salutis\u201d Hospital, Legnago, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"AcademicOncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Specialties (DiMI), Universit\u00e0 degli Studi di Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Giardina","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Medical Oncology, Ospedale Ramazzini di Carpi and Ospedale di Mirandola, Azienda Usl Modena, Carpi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Bertolini","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Division of Medical Oncology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Medical Oncology Unit, Hospital of Brindisi, Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brighenti","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Medical Oncology Department, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Andrini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tognetto","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boni","sequence":"additional","affiliation":[{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"},{"name":"Clinical Epidemiology Unit, IRCSS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy"},{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2025100311543365000_13.5.e010694.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4859"},{"key":"2025100311543365000_13.5.e010694.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0802714"},{"key":"2025100311543365000_13.5.e010694.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00072-7"},{"key":"2025100311543365000_13.5.e010694.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.71"},{"key":"2025100311543365000_13.5.e010694.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"2025100311543365000_13.5.e010694.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.140"},{"key":"2025100311543365000_13.5.e010694.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87"},{"key":"2025100311543365000_13.5.e010694.8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature New Biol"},{"key":"2025100311543365000_13.5.e010694.9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw217"},{"key":"2025100311543365000_13.5.e010694.10","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"2025100311543365000_13.5.e010694.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.04.001"},{"key":"2025100311543365000_13.5.e010694.12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature New Biol"},{"key":"2025100311543365000_13.5.e010694.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.003"},{"key":"2025100311543365000_13.5.e010694.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"2025100311543365000_13.5.e010694.15","doi-asserted-by":"crossref","first-page":"101887","DOI":"10.1016\/j.ctrv.2019.08.003","article-title":"The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers","volume":"79","author":"Gelsomino","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"2025100311543365000_13.5.e010694.16","article-title":"Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1\/Programmed Death-Ligand 1 Blockade in SCLC","volume":"1","author":"Ricciuti","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"2025100311543365000_13.5.e010694.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2025100311543365000_13.5.e010694.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"2025100311543365000_13.5.e010694.19","first-page":"1587","article-title":"Atezolizumab: A Review in Extensive-Stage SCLC","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025100311543365000_13.5.e010694.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"2025100311543365000_13.5.e010694.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1689"},{"key":"2025100311543365000_13.5.e010694.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"2025100311543365000_13.5.e010694.23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100311543365000_13.5.e010694.24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2020.09.003","article-title":"Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study","volume":"149","author":"Goldman","year":"2020","journal-title":"Lung Cancer (Auckl)"},{"key":"2025100311543365000_13.5.e010694.25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092645","article-title":"Adding PD-1\/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials","volume":"12","author":"Facchinetti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100311543365000_13.5.e010694.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9000"},{"key":"2025100311543365000_13.5.e010694.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"2025100311543365000_13.5.e010694.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"2025100311543365000_13.5.e010694.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(02)00112-4"},{"key":"2025100311543365000_13.5.e010694.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017"},{"key":"2025100311543365000_13.5.e010694.31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.3423"},{"key":"2025100311543365000_13.5.e010694.32","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","article-title":"Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial","volume":"35","author":"Tiseo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100311543365000_13.5.e010694.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2014.09.001"},{"key":"2025100311543365000_13.5.e010694.34","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"2025100311543365000_13.5.e010694.35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030675","article-title":"Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents","volume":"9","author":"Ciciola","year":"2020","journal-title":"J Clin Med"},{"key":"2025100311543365000_13.5.e010694.36","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y"},{"key":"2025100311543365000_13.5.e010694.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2176"},{"key":"2025100311543365000_13.5.e010694.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.06.014"},{"key":"2025100311543365000_13.5.e010694.39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025100311543365000_13.5.e010694.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2025100311543365000_13.5.e010694.41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2217\/fon-2021-1027","article-title":"A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale","volume":"18","author":"Andrini","year":"2022","journal-title":"Future Oncol"},{"key":"2025100311543365000_13.5.e010694.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100311543365000_13.5.e010694.43","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT199","article-title":"Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1\/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)","volume":"79","author":"Mansfield","year":"2019","journal-title":"Cancer Res"},{"key":"2025100311543365000_13.5.e010694.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"2025100311543365000_13.5.e010694.45","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"2025100311543365000_13.5.e010694.46","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jtho.2023.09.025","article-title":"OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results","volume":"18","author":"Liu","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2025100311543365000_13.5.e010694.47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01363"},{"key":"2025100311543365000_13.5.e010694.48","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jtho.2016.05.028","article-title":"Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC","volume":"11","author":"Arriola","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025100311543365000_13.5.e010694.49","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100311543365000_13.5.e010694.50","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10637-022-01279-7","article-title":"Anlotinib plus etoposide and cisplatin\/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study","volume":"40","author":"Kong","year":"2022","journal-title":"Invest New Drugs"},{"key":"2025100311543365000_13.5.e010694.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.09.024","article-title":"OA01.03 Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial","volume":"18","author":"Cheng","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2025100311543365000_13.5.e010694.52","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2024.42.16_suppl.8001","article-title":"BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)","volume":"42","author":"Ohe","year":"2024","journal-title":"JCO"},{"key":"2025100311543365000_13.5.e010694.53","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:54:42Z","timestamp":1759517682000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,7]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/jitc-2024-010694"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010694","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}